UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 70,904 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 48.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 218,588 shares of the biopharmaceutical company's stock after acquiring an additional 70,904 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Ocular Therapeutix worth $1,867,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. MetLife Investment Management LLC boosted its holdings in shares of Ocular Therapeutix by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock valued at $792,000 after acquiring an additional 2,454 shares during the last quarter. Teacher Retirement System of Texas lifted its position in Ocular Therapeutix by 10.0% during the fourth quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock valued at $237,000 after purchasing an additional 2,526 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Ocular Therapeutix by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after purchasing an additional 2,853 shares during the last quarter. Cetera Investment Advisers grew its position in Ocular Therapeutix by 0.6% in the 4th quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock worth $6,182,000 after purchasing an additional 4,342 shares during the period. Finally, Wellington Management Group LLP raised its stake in Ocular Therapeutix by 1.0% during the 4th quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock valued at $3,991,000 after buying an additional 4,488 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pravin Dugel sold 21,219 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the transaction, the insider now owns 3,499,099 shares of the company's stock, valued at $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,079 shares of company stock worth $208,739 in the last 90 days. 2.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on OCUL shares. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Needham & Company LLC reduced their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target on the stock. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, William Blair assumed coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock traded down $0.12 during trading hours on Monday, hitting $8.90. The company's stock had a trading volume of 2,305,134 shares, compared to its average volume of 1,409,030. The company has a market cap of $1.42 billion, a PE ratio of -6.74 and a beta of 1.42. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The business has a 50 day moving average price of $7.48 and a two-hundred day moving average price of $7.89. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.